Mon Oct 07 20:34:40 UTC 2024: ## Surgery Partners Receives Moderate Buy Rating from Analysts, Despite Mixed Signals

**Sioux Falls, SD -** Surgery Partners, Inc. (NASDAQ: SGRY) has been awarded a Moderate Buy rating from analysts, according to MarketBeat.com. This rating is based on the combined opinions of seven research firms currently covering the stock, with six analysts issuing a Buy recommendation and one issuing a Hold.

Despite the generally positive outlook, the stock’s performance has been mixed. While the stock saw a slight increase of $0.32 to $32.24 during midday trading on Monday, some analysts have expressed concerns. StockNews.com downgraded SGRY from a Hold to a Sell rating, citing potential risks.

However, other analysts remain optimistic. Benchmark reiterated a Buy rating and issued a $50.00 price target, while Royal Bank of Canada reaffirmed an Outperform rating with a $49.00 price objective. The average 12-month price target among analysts stands at $39.86.

Surgery Partners reported strong earnings in the last quarter, exceeding analysts’ expectations. The company saw a 14.2% increase in revenue year-over-year. However, the company’s net margin remained negative at 1.17%.

Institutional investors are showing continued interest in SGRY, with several funds increasing their stakes in recent quarters. DekaBank Deutsche Girozentrale, Quarry LP, EntryPoint Capital LLC, Capstone Investment Advisors LLC, and Principal Financial Group Inc. all made significant purchases of SGRY shares.

Surgery Partners operates a network of surgical facilities across the United States, offering a range of non-emergency procedures.

While analysts generally remain positive about SGRY’s prospects, some caution is warranted. MarketBeat cautions investors to consider other stocks identified by top analysts before making investment decisions.

Read More